Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Cyrus Daruwalla, Courtney Kremler, Francesco Patti, Serkan Ozakbas et autres
0 citationsBrain
Michal Dufek
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
115Publications signalées
1465Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Sclerosis Research StudiesSystemic Sclerosis and Related DiseasesPeripheral Neuropathies and DisordersPolyomavirus and related diseasesParkinson's Disease Mechanisms and Treatments
Publications récentes
Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study
Riley Bove, Dawn Langdon, Maciej Maciejowski, Elżbieta Jasińska et autres
1 citationJournal of Neurology
Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension (P7-19.003)
Patrick Vermersch, Stephen Krieger, Heinz Wiendl, Cristina Granziera et autres
0 citationsNeurology
Is Cladribine a Suitable Strategy after Natalizumab in MS? Real-world Outcomes (P4-20.007)
Marta Vachova, Dominika Šťastná, Jiří Drahota, Pavel Potužník et autres
0 citationsNeurology
Five-by-Five: Nationwide Real-world Outcomes after ≥Five Years of Cladribine With an Age ≥50 Subanalysis (P2-20.006)
Dominika Šťastná, Marta Vachová, Jiří Drahota, Pavel Potužník et autres
0 citationsNeurology
Tort liability for sports injuries and role of duty care
0 citationsDigital Repository (National Repository of Grey Literature)
3462 Safety and efficacy of frexalimab from the phase 2 open-label extension in participants with relapsing multiple sclerosis: 2-year results
Patrick Vermersch, Cristina Granziera, Yang Mao‐Draayer, Gary Cutter et autres
0 citations
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
Amit Bar-Or, Michal Dufek, Hrvoje Budinčević, Jelena Drulović et autres
30 citationsThe Lancet Neurology
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis
Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres
0 citationsNeurology
Native compilation for R functions
0 citationsCzech Technical University Digital Library (Czech Technical University in Prague)
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis
Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres
9 citationsNeurology
Safety and Efficacy of Frexalimab from the Phase 2 Open-label Extension in Participants with Relapsing Multiple Sclerosis: 2-year Results (S3.006)
Patrick Vermersch, Cristina Granziera, Yang Mao‐Draayer, Gary Cutter et autres
0 citationsNeurology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.